ADVERTISEMENT
Search

 

Press Releases

 

14

Apr

2023

APhA applauds HHS for extending PREP Act authorities for pharmacy personnel

Author: James Keagy

The American Pharmacists Association (APhA) commends the U.S. Department of Health and Human Services (HHS) for announcing that they will ensure that patients can continue to get COVID-19–related care from their pharmacists. APhA is grateful that HHS listened to the concerns of APhA and others in the pharmacy community in expressing a need for HHS to clarify the role of pharmacists and pharmacy teams when the public health emergency expires on May 11, 2023.

Comments (0)
Number of views (7257)
Article rating: No rating

7

Apr

2023

APhA statement related to Texas District Court decision regarding mifepristone

The American Pharmacists Association released the following statement in response to the decision in the Alliance for Hippocratic Medicine v U.S. Food and Drug Administration lawsuit file in the US District Court for the Northern District of Texas, regarding FDA approval of mifepristone. 

Comments (0)
Number of views (5745)
Article rating: No rating

24

Mar

2023

More Than 190 Groups Applaud Bipartisan Federal Legislation to Ensure Senior Access to Essential Pharmacist Services & Strengthen Our Nation’s Public Health Response

Author: James Keagy

H.R. 1770 Would Provide Payment for Pharmacist Services for COVID-19, Flu, Strep & RSV Under Medicare Part B and Ensure Pharmacists Can Continue to Protect Vulnerable Senior Communities

Comments (0)
Number of views (6833)
Article rating: No rating

20

Mar

2023

APhA applauds new federal bipartisan PBM legislation

The American Pharmacists Association (APhA) applauds the introduction of the Drug Price Transparency in Medicaid Act, which would reign in PBMs’ unfair and anticompetitive business practices that are harming the viability of our nation’s pharmacies.

Comments (0)
Number of views (2382)
Article rating: No rating

17

Mar

2023

FDA finalizes guidance on definitions of “suspect product” and “illegitimate product” for existing verification obligations under DSCSA

Author: James Keagy

FDA released final guidance this week that will help dispensers better understand their obligations under the Drug Supply Chain Security Act (DSCSA) related to “suspect” and “illegitimate” products.

Comments (0)
Number of views (2572)
Article rating: No rating
RSS
First34568101112Last
ADVERTISEMENT